Target-directed cancer: protein-ligand interactions
Drug Target Review
NOVEMBER 1, 2023
Capivasertib originated from a collaboration between my former company Astex Pharmaceuticals and the ICR and was further developed by AstraZeneca. In 2001, he joined Astex Pharmaceuticals in Cambridge where he became an expert in fragment-based drug discovery working on diabetes, thrombotic and oncology drug targets.
Let's personalize your content